INOVIO Awaits FDA Decision on INO-3107 as Cash Runway Extends into 2027 — INOVIO Pharmaceuticals, Inc.

Event summary

INOVIO's Biologics License Application (BLA) for INO-3107, targeting Recurrent Respiratory Papillomatosis (RRP), advances toward an FDA PDUFA target date of October 30, 2026.
Company engaged Syneos Health for commercial launch preparations, including Medical Science Liaisons and contract sales organization support.
ApolloBio reported positive Phase 3 trial results for VGX-3100 in China, meeting primary efficacy endpoints for cervical dysplasia treatment.
INOVIO's cash runway extends into late Q1 2027, supported by a $18.3 million equity offering in July 2026.

The big picture

INOVIO's focus on DNA medicines positions it in a competitive biotech landscape where regulatory milestones and commercial execution are critical. The company's strategic partnerships and financial discipline aim to support its pipeline, but success hinges on the FDA's decision on INO-3107 and the ability to sustain operations through potential product launches.

What we're watching

Regulatory Approval: Whether the FDA will grant accelerated approval for INO-3107 by October 30, 2026, and the impact of any feedback on confirmatory trial design.
Commercial Readiness: The pace at which INOVIO can scale its commercial operations for a potential INO-3107 launch, including partnerships with Syneos Health and other key players.
Financial Sustainability: How long INOVIO's current cash position will last beyond late Q1 2027, especially if additional capital-raising activities are not undertaken.